New research from the University of California San Diego finds that chronic administration of cannabidiol (CBD) may significantly reduce alcohol dependence and prevent alcohol-induced brain damage, offering new hope for the treatment of alcohol use disorder (AUD).
Published in the journal Neuropsychopharmacology, the study used two rodent models to simulate key features of human alcohol addiction: chronic intermittent ethanol exposure and ethanol vapor self-administration. In both models, CBD was found to reduce voluntary alcohol intake, ease withdrawal symptoms, and lower the likelihood of relapse.
Researchers found that CBD reduced alcohol-seeking behavior during withdrawal and extinction phases without affecting alcohol metabolism or causing sedation. CBD also alleviated anxiety and physical signs of withdrawal, key factors driving continued use and relapse in AUD. Electrophysiological testing revealed that CBD helped normalize neuronal activity in the basolateral amygdala, a brain region linked to emotional processing and addiction.
The study also showed that CBD prevented neurodegeneration in brain regions associated with reward and habit formation, including the nucleus accumbens shell and dorsomedial striatum. Importantly, CBD’s effects appeared specific to alcohol-related behavior, with no impact on saccharin self-administration.
Researchers highlighted the potential of CBD as a non-intoxicating treatment option that interacts with multiple receptor systems, including serotonin and cannabinoid pathways, without increasing sedation or abuse potential. They also noted that the plasma levels of CBD in rats mirrored those seen in human clinical trials, supporting the study’s translational relevance.
While no major sex differences were observed in the rat models, the authors called for future research to explore sex-specific effects, given known differences in AUD between men and women.
The findings support CBD’s promise as a multifaceted treatment for alcohol addiction and reinforce the need for clinical trials to evaluate its efficacy and optimal dosing in human patients.
More articles from The Marijuana Herald can be found below.
